Dangerous Drugs Menu

Receive a Free
Legal Consultation

  • This field is for validation purposes and should be left unchanged.

Please note: the information on this page is provided for informational purposes only. As of 2011, Simmons Hanly Conroy is no longer accepting cases involving Bextra.

Bextra joined the then-growing list of Cox-2 Inhibitors on the billion dollar pain reliever market in 2001. Bextra (Valdecoxib) belongs to a family of medications referred to as nonsteroidal anti-inflammatory drugs or NSAIDS. Treatment with the use of Bextra is prescribed primarily for pain associated with arthritis, acute pain or painful menstrual cycles.

Bextra initially had a reputation as a type of miracle drug, as it seemed to work better than traditional NSAIDS, such as ibuprofen or aspirin. One benefit of Bextra was that it provided pain relief without the serious problems associated with stomach ulcers, such as bleeding. This side effect was associated with long term use of other NSAIDS.

Cox-2 Inhibitors including Bextra were later cited in several studies as significantly increasing the chance of heart attack or stroke in people who have taken the drugs. Because of this, the FDA withdrew Bextra from the market on April 7, 2005.

Health Complications and Bextra Lawsuits

Numerous side effects, some more serious than others, have been linked to Bextra use. These include:

  • Heart attack
  • Stroke
  • Headache
  • Abdominal pain
  • Diarrhea
  • Nausea
  • Flatulence
  • Insomnia

Simmons Hanly Conroy no longer accepts Bextra lawsuit cases. Learn more about past litigation areas of the pharmaceutical lawyers at the firm, or explore more information on our current areas of litigation. Please contact us with any questions.

Clint Fisher

Shareholder Clint Fisher

Many of our pharmaceutical attorneys have national leadership experience with Bextra lawsuits. In 2006, Shareholder Paul Hanly was court-appointed to three positions: as a member of the Plaintiffs’ Coordinating Committee in the coordinated New York State Bextra and Celebrex Products Liability Litigation, as liaison counsel between those proceedings and their federal multidistrict litigation (“MDL”) counterpart, and as a member of the MDL Plaintiffs’ Steering Committee. Also in 2006, Shareholder Jayne Conroy was selected to serve leading roles on the Discovery and Science Committees in those two litigations. Shareholder Clint Fisher was added to the Discovery Committee in 2007. Shareholder Mitchell Breit served on the New York State Court Liaison Counsel in Bextra and Celebrex Marketing, Sales Practices and Products Liability Litigation. Shareholders Trent Miracle and David Miceli also have federal leadership experience with Bextra litigation.

Client Testimonials

I am very pleased and had a wonderful experience with the firm. Would definitely use their services again.

View More Testimonials

- Margaret

202 queries. 0.668 seconds